A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
← catalyst calendarNCT06735248 · readout in 873 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
180estimated
Sites
17
Countries
Australia, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-16 | actual | When the study began enrolling |
| Primary completion | 2029-01-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-08 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Interventions
- Biological: mRNA-1195
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
measured Up to Day 176 (7 days after each study injection)
Number of Participants with Unsolicited Adverse Events (AEs)
measured Up to Day 197 (28 days after each study injection)
Number of Participants with Medically Attended Adverse Events (MAAEs)
measured Up to Day 347 (up to 6 months after last study injection)
Number of Participants with Adverse Events of Special Interest (AESI), Serious Adverse Events (SAEs) and AEs Leading to Discontinuation of Study Intervention and/or Study Participation
measured Up to Day 887 (end of study)
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed